Hexen

From PsychonautWiki
Jump to: navigation, search
Summary sheet: Hexen
Hexen
Molecular structure of Hexen
N-ethyl-nor-hexedrone.svg
Chemical Nomenclature
Common names Hexen, Hex-en, NEH, Ethyl-Hexedrone
Substitutive name N-Ethylhexedrone
Systematic name 2-(ethylamino)-1-phenylhexan-1-one
Class Membership
Psychoactive class Stimulant
Chemical class Cathinone
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.


Smoked
Dosage
Threshold 1 - 2 mg
Light 2 - 5 mg
Common 5 - 10 mg
Strong 10 - 20 mg
Heavy 20 mg +
Duration
Total 1 - 4 hours
Onset 2 - 10 minutes
Peak 10 - 30 minutes
Offset 15 - 30 minutes
After effects 2 - 4 hours




Insufflated
Dosage
Threshold 5 - 15 mg
Light 15 - 30 mg
Common 30 - 40 mg
Strong 40 - 50 mg
Heavy 50 mg +
Duration
Total 2 - 5 hours
Onset 2 - 8 minutes
Peak 30 - 90 minutes
Offset 1 - 4 hours
After effects 1 - 8 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

N-Ethylhexedrone (also known as N-Ethyl-nor-hexedrone, NEH, and commonly as Hexen) is a novel synthetic stimulant of the cathinone chemical class that produces classical stimulant effects such as stimulation, disinhibition, thought acceleration, and euphoria when administered. Its effects are believed to be caused by its activity as an NDRI (norepinephrine-dopamine reuptake inhibitor), although this has yet to be scientifically validated.[citation needed]

As with many of its research chemical cathinone predecessors, Hexen is known to come in the form of either a white powder or crystallized shards[citation needed] which users can ingest to produce a powerful, fast-acting but short-lived euphoric stimulant effects which are comparable to those produced by crack-cocaine, NEP and α-PVP-type compounds, particularly when they are insufflated, vaporized or injected.[citation needed]

Like other short-lived substituted cathinone compounds, Hexen has gained notoriety for its associated tendency to induce compulsive redosing and addictive behaviors in a seemingly significant percentage of its users as well the ability to readily induce paranoia, anxiety, various delusional states and stimulant psychosis when abused, taken too frequently or in excess.[citation needed]

Hexen was first synthesized in 2011 but became widely available in the research chemical market during late 2015, upon which it rapidly gained popularity. It is a prominent example of a contemporary designer drug specifically chosen to mimic and/or replace the functional and structural features of its recently-controlled predecessors, which are sometimes imprecisely grouped together by the media as "bath salts".[citation needed]

Little research exists about both Hexen as well as its parent compound, hexedrone, particularly with regards to its toxicity, addiction, and abuse potential. Due to its novelty and extremely short history of human usage, all information related to the use of this compound should be treated with caution.

Chemistry

Hexen, or N-ethylhexedrone, is a molecule of the substituted cathinone chemical class. The term "substituted cathinone" refers to a broad array of substances based on cathinone, the principally active constituent of the khat plant. Cathinone is principally constituted of a phenethylamine core with an alkyl group attached to the alpha carbon and an oxygen group attached to the beta carbon. Cathinones are also known as the beta-ketone (double-bonded oxygen to the β-carbon) analogs of amphetamines.

Notably, the cathinone backbone can be modified in three different places to create hundreds of possible compounds, which include substituents on the aromatic ring, the alpha carbon, and the amine group.[1]

Pharmacology

Due to the lack of research regarding the substance, all proceeding discussion regarding the pharmacology of this compound derives from speculation based upon its structure and subjective effect similarities to other substituted cathinones such as NEP (N-ethyl-(nor)-pentedrone), pentedrone, a-PVP, and a-PHP and others.

Hexen most likely acts as both a dopamine and norepinephrine releasing agent or reuptake inhibitor.[citation needed] This allows the endogenous neurotransmitters dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects.[citation needed]

The pharmacology of N-ethylhexedrone can perhaps be compared to the much better known pentedrone. Hexedrone is an extended chain version of pentedrone, differing by a single carbon on the alpha-alkyl chain. It should be noted that extension of the carbon chain in this manner generally results in less potency than the parent compound. However, the addition of the ethyl group to the terminal amine (-NH2) group seems to counteract this and increase its potency significantly, much like is observed with NEP (N-Ethyl-(nor)-Pentedrone).

Subjective effects

Metacogghjgjvghnition.png
This subjective effect breakdown is a stub.

As such, it may contain incomplete or wrong information and is still in progress.

You can help by expanding it.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.

Physical effects
Child.svg

Cognitive effects
User.svg

After effects
Aftereffects (3).svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational Hexen use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because Hexen has a very brief history of human usage. Early anecdotal evidence from people who have tried Hexen within the community suggests that there do not seem to be any negative health effects attributed to simply trying it at low to moderate doses by itself and using it in a sparing and controlled fashion (but nothing can be completely guaranteed).

Some users have reported Hexen to be caustic to the nasal membrane when it is insufflated.[citation needed]

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other stimulants, the chronic use of Hexen can be considered moderately addictive with a high potential for abuse and seems to be readily liable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of Hexen develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the total absence of further consumption). Hexen presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of Hexen all stimulants will have a reduced effect.

Psychosis

Main article: Stimulant psychosis

Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions).[2] A review on treatment for (dextro)amphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[3][4] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[5]

Dangerous interactions

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Legality

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[7]
  • Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[8]
  • Poland - The legal situation is unclear and we currently have no information about the legality of this substance.
  • Sweden - N-Ethylhexedrone was classified as an illegal narcotic in Sweden on June 21st, 2016.[9]

See also

External links

References

  1. Liu, C., Jia, W., Li, T., Hua, Z., & Qian, Z. (n.d.). Identification and analytical characterization of nine synthetic cathinone derivatives N-ethylhexedrone, 4-Cl-pentedrone, 4-Cl--EAPP, propylone, N-ethylnorpentylone, 6-MeO-bk-MDMA, -PiHP, 4-Cl--PHP, and 4-F--PHP. https://doi.org/10.1002/dta.2136
  2. Treatment for amphetamine psychosis | [1]
  3. Treatment for amphetamine psychosis | [2]
  4. Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
  5. Treatment for amphetamine psychosis | [3]
  6. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
  7. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted
  8. http://portal.anvisa.gov.br/documents/33868/3233596/56+-+RDC+N%C2%BA+159-2017-DOU.pdf/27be30ee-3884-46fe-b7ba-ae2f94b74693
  9. 31 nya ämnen kan klassas som narkotika eller hälsofarlig vara | https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/juni/31-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara/